http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2328747-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1927fb5bec3927bad638ea627a16e721 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d40960190e37af1e3390c21a67554f98 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_648c15a91ad38a5e43585ef62955658b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_80ea52df622383c2e8bba7e16c3787e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d2536d25c606cf230e24d4f94045e92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9239e9e0cd24d10b4707bcaef14d8392 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 |
| filingDate | 2007-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2008-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76ed52911c6ce8122f37aa81d274bc85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5297cc99a9652a2d4fb0c3df5abae269 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86a3deed9f55f4c70fd6fe56b1b18c9e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab6ed44d127285e9b8e29bd9498ad912 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a231ab69646ef162e93896e2190ab451 |
| publicationDate | 2008-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2328747-C1 |
| titleOfInvention | Method of provided efficiency of non-adjuvant autohemochemotherapy for patients suffering from paget-type breast cancer |
| abstract | FIELD: medicine; oncology. n SUBSTANCE: patient's blood is tested prior to and after radioimmunotherapy for contents of progesterone, estradiol, follicle- and lutein-stimulating hormones. Patients after treatment are diagnosed with increased progesterone amount from 1.50 to 4.7 nmole/l, reduced ratio of follicle-stimulating to lutein-stimulating hormones from 0.88 to 0.32 and reduced ratio of estradiol to progesterone from 208 to 117, and tumour regression is diagnosed with reduction of progesterone from 0.95-1.34 nmole/l to 0.41-0.83, increased ratio of follicle-stimulating to lutein-stimulating hormones from 0.83-3.81 to 2.07-4.41 and reduced ratio of estradiol to progesterone from 205.2-328.4 to 255.8-671.1. n EFFECT: method application allows detecting of autohemochemotherapy efficiency within postoperative period for patients suffering from Paget-type breast cancer, providing further therapy course correction. n 1 tbl, 2 ex |
| priorityDate | 2007-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.